Study #2023-0288
A phase 1, open-label, multicenter study of INCA33890 in participants with advanced or metastatic solid tumors.
MD Anderson Study Status
Enrolling
Treatment Agent
INCA33890
Description
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Study phase:
Phase I
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-391-3015
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.